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Abstract 
Background: Bone Scan Index (BSI) expresses tumor burden in bone as a percentage of total skeletal mass, but its 
significance for metastatic breast cancer patients is unknown. We investigated whether baseline BSI is associated with 
skeletal-related events (SREs) or survival and identified the cut-off BSI score for predicting SREs in metastatic breast 
cancer patients.
Methods: We retrospectively reviewed 144 patients with bone metastatic breast cancer. Bone scan examinations 
were performed and BSI was calculated using the Bonenavi® automated method. All patients received standard 
medical treatment for metastatic breast cancer. For bone metastasis prophylaxis, bisphosphonates were infused ini-
tially with analgesics as needed. We defined SRE as either bony, requiring intervention (surgery and/or radiotherapy) 
for pain or prevention of fracture, or spinal cord compression. The rates of SRE and overall survival (OS) were evalu-
ated according to baseline BSI, and the cut-off score of BSI for predicting SRE in metastatic breast cancer patients was 
identified.
Results: Thirty-three patients (25.6 %) had SREs. The median BSI was 1.08 % (inter-quartile range 0.50–3.23 %). To 
identify the cut-off BSI score for predicting SRE, we performed sensitivity analysis to check P-value at every 0.1 BSI 
interval (0.4–2.4) by multiple-variable proportional hazard analysis. A BSI cut-off point of 1.4 % showed the lowest P 
value. Patients with BSI scores ≥1.4 had a significantly higher rate of SRE than those with lower BSI (P = 0.022). How-
ever there was no significant difference in OS.
Conclusion: BSI may predict SRE in patients with metastatic breast cancer. A high BSI value (≥1.4) at diagnosis of 
bone metastasis may be a predictor of SREs in bone metastatic breast cancer patients.
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Background
Breast cancer is known to be associated with a high inci-
dence of bone metastasis (Coleman and Rubens 1987; 
Hamaoka et  al. 2004; Koizumi et  al. 2010a, b), which 
causes skeletal-related events (SREs), including pain, 
bone fractures, spinal cord compression and hypercalce-
mia, significantly impairing patients’ quality of life (Costa 
and Major 2009; Onishi et  al. 2010; Sturge et  al. 2011). 
Early detection of metastatic disease may therefore pre-
vent these complications, offer a better chance to control 
the disease process and result in better survival and bet-
ter quality of life (Koizumi et al. 2010a, b). For diagnosis 
of bone metastasis, bone scintigraphy has good sensitiv-
ity (Costelloe et  al. 2009) and has been regarded as the 
first alternative imaging method capable of diagnosing 
asymptomatic bone metastasis because it is readily avail-
able and provides an entire skeletal visualization within a 
reasonable amount of time and at a reasonable cost (Liu 
et al. 2011). It is widely used for patients with carcinoma 
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to detect skeletal metastasis despite advances in other 
modalities such as PET-CT and MRI, although routinely 
examination is not always recommended in breast can-
cer patients. It can help diagnose a number of conditions 
relating to bones, including cancer of the bone or can-
cers that have metastasized to bone, although its find-
ings are frequently non-specific because the uptake of 
99mTc-methyl diphosphonate depends on the integrity of 
osteoblasts and on matrix activity. There is the problem 
of mixed breast cancer metastasis (lytic and sclerotic). 
Indeed, lytic lesions are underestimated by bone scan 
and less well visualized also by Bone Scan Index (BSI), 
which is less the case for cancer of the prostate, where 
the lesions are almost all sclerotic therefore with a scin-
tigraphy hot spot appearance. In breast cancer, the lytic 
lesions can be having the pattern of discreetly uptake or 
normally uptake but rarely with hot spot appearance.
On a per patient basis, the pooled sensitivity estimates 
for bone scintigraphy is 87.0 % and the pooled specific-
ity estimates is 88.1  % in detecting bone metastases in 
patients with breast cancer (Liu et  al. 2011). In addi-
tion an appropriate approach for quantitative analysis is 
required.
BSI has been developed as a quantitative tool to 
improve the interpretability and clinical relevance of 
bone scanning, making it possible to show the bone 
metastatic tumor burden (Erdi et al. 1997; Imbriaco et al. 
1998). BSI has recently been reported as a response indi-
cator in patients with metastatic prostate cancer (Dennis 
et  al. 2012), as well as a prognostic indicator (Sabbatini 
et  al. 1999). However, few studies have examined the 
significance of BSI for metastatic breast cancer patients 
(Colombié et al. 2013; Iwase et al. 2014).
The aims of this study were twofold: first, to explore 
whether baseline BSI was associated with SRE or survival 
and second, to identify the cut-off score of BSI for pre-
dicting SRE in metastatic breast cancer patients.
Patients and methods
We retrospectively reviewed all breast cancer patients’ 
data from Aichi Cancer Center Hospital’s database 
between 2002 and 2012. Patients comprised 144 indi-
viduals with bone metastatic breast cancer, who had 
undergone whole body bone scan examinations in our 
institution at diagnosis of bone metastasis. The defini-
tion of bone metastasis was done by imaging findings 
such as X-ray examination, CT or MRI scan as well as 
subjective symptoms and bone scan. Bone scan exami-
nations were performed 3  h after intravenous injection 
of 740 MBq 99mTc-methyl diphosphonate (FUJIFILM RI 
Pharma Co., Ltd., Tokyo, Japan), using nuclear medicine 
imaging procedures to detect radioisotope tracer uptake 
in the patient’s body (Infinia HE4®, GE healthcare, Tokyo, 
Japan). A gamma camera equipped with a low-energy 
high-resolution parallel whole collimator was used at 
anterior and posterior view scan speeds of 15  cm/min 
(matrix 256 × 1024). Energy discrimination was provided 
by a 10 % window centered on the 140 keV of the Tc99m. 
BSI was calculated first by determining the percentage of 
each bone that is involved by the tracer in relationship 
to the total skeletal mass, as determined from reference 
man, which is using the Bonenavi® automated method 
(FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan). We retro-
spectively reviewed imaging data to analyze BSI without 
having any clinical information of the patient. If patients 
had taken bone scan examinations more than twice, we 
analyzed the image at the time of bone metastasis ini-
tially. We excluded the scan data if it is before or after 
three months from the day of diagnosis.
All patients received standard systemic therapy for 
metastatic breast cancer, including chemotherapy, hor-
mone therapy, and anti-HER2 therapy. For prophy-
laxis against SRE, bisphosphonates or denosumab were 
infused initially with analgesics as needed. We defined 
SRE as either bony, requiring intervention (surgery and/
or radiotherapy) for pain or prevention of fracture, or 
spinal cord compression, and recorded the date on which 
an SRE was first observed. Patients with an SRE before 
bone scan examination were excluded. SRE-free survival 
was recorded from the date of baseline bone scanning 
to the SRE date. Overall survival (OS) was also recorded 
from the baseline bone scan to death. Written informed 
consent was obtained from all patients and this study 
has been approved in our institution (approved number: 
2015-1-058).
The intrinsic subtype of primary tumor was classified 
using immunohistochemical (IHC) staining of paraffin-
embedded thin sections as follows: luminal: ER and/or 
PgR positive (stained proportion >10 %), HER2 negative; 
luminal-HER2: ER and/or PgR positive and HER2 posi-
tive; HER2: ER negative, PgR negative and HER2 positive; 
triple negative: ER negative PgR negative and HER2 nega-
tive. A diagnosis of HER2 positive cancer was based on 
the published guidelines (Wolff et al. 2007).
The purpose of this study was to evaluate the rate of 
SRE and OS according to the baseline BSI, and to iden-
tify the cut-off score of BSI for predicting SRE in meta-
static breast cancer patients. We performed sensitivity 
analysis checking P values for SRE at intervals of 0.1 from 
0.4 to 2.4 % using a Cox regression model. We used the 
BSI score with the lowest P values as the cut-off point. 
To estimate the distribution of SREs and survival data, 
Kaplan–Meier estimates were used together with the log-
rank test. Multivariate analyses were conducted using 
the Cox proportional hazard model. Factors evaluated in 
the model included age, metastasis site other than bone, 
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performance status, and intrinsic subtype as well as the 
cut-off point of BSI. P values less than 0.05 were consid-
ered statistically significant. All statistical analyses were 
conducted using STATA® v.12.1 (StataCorp, College Sta-
tion, TX, USA).
Results
Of the 144 patients who underwent a bone scan at meta-
static diagnosis, 15 were found to have had SREs before 
the bone scanning date and were excluded, leaving 129 
patients who were enrolled in the study. Patient char-
acteristics are shown in Table  1. The median age was 
57  years old (range 31–84) and ECOG performance 
status (PS) were 0–2, which are listed in Table  1. The 
proportion of each intrinsic subtype was as follows: lumi-
nal type; 66.2  % (n  =  85), luminal HER2 type; 18.6  % 
(n = 24), HER2 type; 7.6 % (n = 10) and TN type; 7.6 % 
(n  =  10). Almost all of the patients (95.3  %) had been 
treated with zoledronic acid and/or denosumab while five 
(3.9  %) received other bisphosphonate drugs. Twenty-
three patients (17.8  %) had other distant metastases 
at baseline. The median BSI was 1.08  % (inter quartile 
range 0.50–3.23 %). The median follow up time for SRE 
was 2.04  years, and for OS was 2.50  years, respectively. 
During the clinical course, 33 patients (25.6 %) had SREs. 
Among them, 5 patients underwent surgical therapy and 
28 patients were treated by irradiation.
A BSI cut off-point of 1.4 % showed the lowest P value 
in multivariate analysis (Fig.  1). Twenty patients with 
higher BSI (≥1.4) and 13 patients with lower BSI (<1.4) 
had SREs. Figure  2 shows the Kaplan–Meier curves for 
SREs of the two groups. Patients with BSI ≥1.4 had signif-
icantly more SREs than those with BSI <1.4 (P = 0.022). 
The results of multivariate analysis for the risk of SREs 
are summarized in Table 2. Higher BSI (≥1.4) was a sig-
nificant predictive factor (hazard ratio; HR 2.37; 95 % CI 
1.13–4.95, P = 0.022), but other factors [age, metastasis 
organ, performance status (PS), intrinsic subtype] had no 
association with SRE. Kaplan-Meier analysis of OS in the 
two groups (Fig. 3) did not show any significance at that 
cutoff point (P =  0.436). Table  3 shows the association 
between OS and clinical factors including BSI. Higher 
BSI was not a prognostic factor for OS. The patients with 
PS2 or triple negative breast cancers had worse prognosis 
(HR 4.09; 95 % CI 1.41–11.9, P = 0.010, HR 2.94; 95 % CI 




 ≥50 93 (72.1)
 <50 36 (27.9)
 Median age (range) 56 (31–84)
PS
 0 83 (64.3)
 1 39 (30.2)
 2 7 (5.4)
Intrinsic subtype
 Luminal 85 (66.2)
 Luminal-HER2 24 (18.6)
 HER2 10 (7.6)
 Triple negative 10 (7.6)
Metastasis site with bone
 Brain 3 (2.3)
 Liver 13 (10.1)
 Lung 9 (7.0)
Zoledronic acid and/or denosumab use 121 (95.3)
Other bisphosphonate use 5 (3.9)
Median BSI (%) 1.08
Inter quartile range (%) 0.50–3.23
SRE 33 (25.6)
 Surgical therapy received 5 (3.9)
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Fig. 1 Sensitivity analysis for SRE by Cox regression model. A value of 
1.4 for BSI showed the lowest P value in multivariate analysis
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1.22–7.09, P = 0.016, respectively), but other factors were 
not statically significant.
Discussion
This study is the first to report the clinical significance of 
evaluating BSI when bone metastasis occurs in patients 
with metastatic breast cancer. Our results showed that 
the higher BSI group had a significantly higher rate of 
SRE than that of the lower BSI group. A BSI cut-off point 
of 1.4 % showed the lowest P value by multivariate analy-
sis. At the cut-off point of 1.4 %, the higher BSI group had 
a significantly worse SRE rate than the lower BSI group. 
However, we found no statistically significant difference 
in OS.
BSI is a computer-assisted diagnosis system that elimi-
nates differences between radiologists. The original BSI 
system was developed using a Swedish database (Sadik 
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Fig. 2 Kaplan–Meier curves for SRE (BSI cut off = 1.4). Patients 
with BSI ≥ 1.4 had significantly more SREs than those with BSI < 1.4 
(P = 0.022). The median follow up time for SRE was 2.04 years
Table 2 Multivariate analysis for SRE
Hazard ratio 95 % CI P value
BSI
 <1.4 1.0 Ref.
 ≧1.4 2.37 1.13 4.95 0.022
Age
 <50 1.0 Ref.
 ≧50 0.94 0.45 2.33 0.944
Metastasis site
 Bone only 1.0 Ref.
 Brain N.E – – –
 Liver 1.35 0.34 5.41 0.675
 Lung 0.99 0.22 4.53 0.990
PS
 0 1.0 Ref.
 1 1.06 0.47 2.40 0.890
 2 2.030 0.45 9.10 0.354
Intrinsic subtype
 Luminal 1.0 Ref.
 Luminal HER2 1.52 0.65 3.55 0.330
 HER2 0.98 0.22 4.44 0.980
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Fig. 3 Kaplan–Meier curves for OS (BSI cut off = 1.4). It did not show 
any significance at that cutoff point (P = 0.436). The median follow up 
time for OS was 2.50 years
Table 3 Multivariate analysis for OS
Hazard ratio 95 % CI P value
BSI
 <1.4 1.0 Ref.
 ≧1.4 1.24 0.72 2.16 0.436
Age
 <50 1.0 Ref.
 ≧50 0.91 0.50 1.66 0.768
Metastasis site
 Bone only 1.0 Ref.
 Brain 6.91 0.75 63.8 0.089
 Liver 1.58 0.66 3.80 0.308
 Lung 1.21 0.39 3.69 0.741
PS
 0 1.0 Ref.
 1 1.42 0.79 2.57 0.241
 2 4.09 1.41 11.9 0.010
Intrinsic subtype
 Luminal 1.0 Ref.
 Luminal HER2 1.48 0.77 2.86 0.244
 HER2 2.10 0.82 5.37 0.122
 Triple negative 2.94 1.22 7.09 0.016
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bone® (EXINI Diagnostics AB, Sweden), and is a com-
mercially-available software package using a Japanese 
database (n = 904) (Horikoshi et al. 2012). The sensitivity 
of Bonenavi® in diagnosing bone metastasis is 90 % and 
the specificity is 81 %, thus it is expected to be a better 
bone management tool (Horikoshi, et al. 2012). Recently 
this was revised to produce version 2, constructed from 
the database of 9 Japanese institutions (Nakajima et  al. 
2013). The feasibility of Bonenavi® version 2 has been 
reported, and its accuracy is reportedly as good as ver-
sion 1 (Koizumi et al. 2015).
In a study by Dennis et al. (2012) of patients with cas-
tration-resistant metastatic prostate cancer who received 
chemotherapy, BSI was found to be a response indica-
tor. Indeed, they studied bone scans at baseline and at 3 
and 6 months in different patients and BSI changes post-
treatment were found to be a significant prognostic fac-
tor for survival (Dennis et al. 2012).
The results showed the feasibility of capturing bone 
scintigraphy data as a single quantitative measure and 
thereby allowing a bone scan to be explored for imag-
ing biomarkers. Furthermore, changes in BSI post-
treatment were significantly associated with survival, 
but post-treatment changes in PSA were not, while 
adjusting for changes in BSI. However the clinical 
impact of BSI in metastatic breast cancer patients is 
not yet known. One reason for the differences between 
castration-resistant metastatic prostate cancer and 
metastatic breast cancer may be that the mortality of 
metastatic breast cancer patients depends on control of 
metastasis to distant organs by chemotherapy or hor-
monal therapy.
In patients with metastatic breast cancer, therapy with 
bone-modifying agents is recommended to prevent the 
development of osteoporosis and SRE (Van Poznak et al. 
2011). However extended exposure is associated with 
osteonecrosis of the jaw (Durie et  al. 2005; Migliorati 
et  al. 2006), so the timing of starting treatment with a 
bone-modifying agent is important. BSI may be helpful 
for selecting patients at high risk of SRE so that treatment 
with bone-modifying agents can be appropriately tar-
geted, or choosing patients at low risk of SRE who are not 
necessary using bone-modifying agents.
The strength of this study is that it provides the first 
suggestion that BSI at diagnosis of bone metastasis is 
predictive for SRE. A limitation of this study is that treat-
ment for metastatic breast cancer was heterogeneous 
because the study is retrospective. Brain metastasis had 
a trend as a prognostic factor for OS by the multivari-
ate analysis, this is because only three patients were with 
brain metastases; it must be due to the weakness of the 
small number of this subgroup. There was also some vari-
ation in the length of time between the date of diagnosis 
of metastasis and the date of bone scan examination. As a 
next step, a prospective study to validate the clinical sig-
nificance of BSI is needed.
Conclusion
BSI may predict SREs in patients with metastatic breast 
cancer. The high cut-off level of BSI (≥1.4) at diagnosis 
of bone metastasis may be a predictor for SREs in bone 
metastatic breast cancer patients.
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